Last Change % Change
SPY 234.59 -0.75 -0.32%
DIA 205.25 -0.27 -0.13%
IWM 137.21 -0.31 -0.23%
QQQ 132.56 -0.03 -0.02%

Prices may be delayed by 15 minutes or more.

Biotech focus


AXIM Biotech: New Clinical Program Featured in National Ophthalmology Publication Reignites Hope for Glaucoma Cannabis Therapy

In this article, we look at AXIM Biotechnologies Inc.’s (OTCQB: AXIM) progress in ophthalmology and why investors should take note. AXIM Biotech, a company specializing in cannabinoid research and development, is committed to developing cannabinoid-based therapies for glaucoma and dry eye. In addition to ophthalmology, the company has developed a robust clinical pipeline targeting a wide array of medical conditions with various delivery platforms and technologies.

AXIM Biotech Launches Marinol®-Bioequivalent Chewing Gum Program

AXIM Biotech Signs CRO deal for its Ophthalmology Treatments Clinical Program

What's Behind AXIM's Chewing Gum Focus?

New CBD-Infused Chewing Gum Promises Enhanced Bioavailability

AXIM Biotech Offers the Broadest Pipeline in the Cannabis Industry